Moderate-severe alcohol use disorder (AUD), cannabis use disorder (CaUD), cocaine use disorder (CoUD), opioid use disorder (OUD), or other drug* use disorder Mental and Behavioural Disorders
Conditions
Interventions
Study Design: SUPPORT is a multi-centre, open-label, randomised controlled trial evaluating the effectiveness of a structured aftercare intervention for people completing community treatment for alcoh
Sponsors
South London and Maudsley NHS Foundation Trust
King's College London
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age > = 18 years 2. Moderate-severe alcohol use disorder (AUD), cannabis use disorder (CaUD), cocaine use disorder (CoUD), opioid use disorder (OUD), or other drug* use disorder at admission to current treatment episode 3. Able to be contacted by telephone for follow-up during the study period 4. Completion of treatment episode care plan and wish to leave treatment *'Other drugs' refers to psychoactive substances not included in the four primary study groups (alcohol, cannabis, cocaine, opioids). This may include substances such as benzodiazepines, ketamine, and other prescription or non-prescription psychoactive drugs used non-medically.
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 06/07/2026: 1. Current suicide plan or attempt in past 6 months 2. Current criminal justice involvement with legal proceedings (not including current probationary supervision) likely to prevent ability to engage with follow-up 3. Currently enrolled in another interventional research study 4. Previous participation in the SUPPORT trial Previous exclusion criteria: 1. Current suicide plan or attempt in the past 6 months 2. Current risk of a custodial sentence likely to prevent study completion 3. Currently enrolled in another interventional research study 4. Previous participation in the SUPPORT trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of abstinent days from alcohol and drugs, measured using the Timeline Follow-Back (TLFB) interview at baseline, days 30, 60, 90, 150, 180, 210, 270, and 365 | — |
Secondary
| Measure | Time frame |
|---|---|
| Cost-effectiveness measured using the Adult Service Use Schedule (ADSUS) and the health-related quality of life tool EQ-5D-5L at baseline, days 90, 180, 270, and 365;Reduced substance use and craving measured using TimeLine Follow-Back interview (TLFB) for the longest continuous period of abstinence, and a Visual Analogue Scale (VAS) for craving intensity at baseline, days 30, 60, 90, 150, 180, 210, 270, and 365;Remission and patient-reported improvement measured using using the Structured Clinical Interview for DSM-5, Research Version (SCID-5-RV), and the Patient Reported Outcome Severity (PRO-S) and Patient Reported Outcome Improvement (PRO-I) measures. These will be collected at baseline, 3 months, and 12 months for the SCID-5-RV and PRO-S; and at baseline and 365 days for the PRO-I.;Time to SUD treatment re-admission measured using the ADSUS at baseline, days 90, 180, 270, and 365 | — |
Countries
England, United Kingdom
Contacts
Public ContactStephen Lisk
Outcome results
None listed